How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,635 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13901. Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer

or basal cell or squamous cell skin cancer No other uncontrolled concurrent illness that would preclude study participation No ongoing or active infection No psychiatric illness or social situation that would preclude study compliance Must have central or peripherally inserted central catheter PRIOR CONCURRENT THERAPY: Biologic therapy No concurrent filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa Chemotherapy No prior chemotherapy for recurrent or metastatic disease Prior adjuvant (...) Institute (NCI) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy, such as irofulven, use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well irofulven works in treating patients with recurrent or metastatic gastric cancer. Condition or disease Intervention/treatment Phase Gastric Cancer Drug: irofulven Phase 2 Detailed Description

2003 Clinical Trials

13902. Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum

provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ): Sun Exposure Xeroderma Pigmentosum Skin Cancer Family History HETEROZYGOTE XP Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Squamous Cell Carcinoma, Basal Cell Skin Neoplasms Xeroderma Pigmentosum Ichthyosis Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Neoplasms, Basal Cell Neoplasms by Site Skin Diseases (...) examination and composition analysis Surgery to treat skin cancers or other lesions Condition or disease Xeroderma Pigmentosum Melanoma Squamous Cell Carcinoma Basal Cell Carcinoma Skin Cancer Detailed Description: Xeroderma Pigmentosum (XP) is a rare, recessive disorder with a more than 1000-fold increase in the frequency of all major skin cancers in association with defective DNA repair. The risk of skin and other cancers among normal appearing XP heterozygote individuals has not been fully studied. We

2002 Clinical Trials

13903. S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed muscle-invasive (T2-T4a), node-negative (N0) urothelial transitional cell cancer (TCC) of the bladder Focal squamous and/or adenocarcinoma differentiation, defined as ≤ 10% of tumor volume allowed The following diagnoses are not allowed: Small cell carcinoma Sarcomatoid components Disease diagnosed (...) concurrent systemic disorder that would preclude study compliance No other malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer in complete remission, or any other cancer for which patient has been disease-free for 5 years Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy Prior intravesical immunotherapy allowed Chemotherapy No prior systemic

2002 Clinical Trials

13904. PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

asthma requiring chronic systemic steroids Other HIV negative Negative pregnancy test Fertile patients must use effective contraception No malignancy within the past 2 years except basal cell or squamous cell skin cancer, superficial bladder cancer, or localized prostate cancer Patients who have undergone potentially curative therapy and have been deemed to be at low risk for recurrence are eligible No medically significant psychiatric disease (e.g., endogenous depression, psychosis, or bipolar (...) : 01-143 CDR0000256464 ( Registry Identifier: PDQ (Physician Data Query) ) NCI-G-02-2102 First Posted: January 27, 2003 Last Update Posted: June 5, 2013 Last Verified: June 2013 Keywords provided by Memorial Sloan Kettering Cancer Center: stage IV renal cell cancer Additional relevant MeSH terms: Layout table for MeSH terms Kidney Neoplasms Carcinoma, Renal Cell Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Kidney Diseases Urologic Diseases Adenocarcinoma Carcinoma Neoplasms

2002 Clinical Trials

13905. R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence

except basal cell or squamous cell skin cancer No active systemic infections No other serious uncontrolled medical condition No dementia or altered mental status PRIOR CONCURRENT THERAPY: Biologic therapy No concurrent biologic therapy Chemotherapy More than 5 years since prior cytotoxic chemotherapy for other malignant disease No prior cytotoxic chemotherapy for prostate cancer No concurrent chemotherapy Endocrine therapy More than 9 months since prior androgen-deprivation therapy other than (...) ClinicalTrials.gov Identifier: Obsolete Identifiers: NCT00043251 Other Study ID Numbers: CDR0000256371 MYRIAD-MPR-7869-001 First Posted: February 6, 2003 Last Update Posted: December 18, 2013 Last Verified: February 2004 Keywords provided by National Cancer Institute (NCI): adenocarcinoma of the prostate recurrent prostate cancer Additional relevant MeSH terms: Layout table for MeSH terms Prostatic Neoplasms Recurrence Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases

2002 Clinical Trials

13906. Trastuzumab in Treating Women With Primary Breast Cancer

according to Tumor/Node/Metastasis (TNM) staging Completion of at least 4 cycles of (neo-)adjuvant systemic chemotherapy, definitive surgery, and radiotherapy, if applicable Known hormone receptor status Baseline left ventricular ejection fraction (LVEF) greater than or equal to (≥) 55 percent (%) Exclusion Criteria: Prior invasive breast carcinoma Other malignancies except for curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix Clinical T4 tumors (...) included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning

2002 Clinical Trials

13907. Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus

infection No uncontrolled diabetes mellitus (random blood sugar at least 300 mg) No peripheral neuropathy grade 2 or greater No other malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or any other malignancy that does not carry a worse prognosis than advanced esophageal cancer No other serious underlying medical condition that would preclude study No other concurrent disease that would preclude study No psychiatric (...) Posted: June 5, 2013 Last Verified: June 2013 Keywords provided by Memorial Sloan Kettering Cancer Center: stage II esophageal cancer stage III esophageal cancer stage IV esophageal cancer squamous cell carcinoma of the esophagus adenocarcinoma of the esophagus Additional relevant MeSH terms: Layout table for MeSH terms Esophageal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Head and Neck Neoplasms Digestive System Diseases Esophageal Diseases

2002 Clinical Trials

13908. Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

except basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 weeks since prior immunotherapy No prior vaccine with any of the antigens in this study Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy No concurrent chemotherapy Endocrine therapy: See Disease Characteristics Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics At least (...) Keywords provided by Memorial Sloan Kettering Cancer Center: stage I breast cancer stage II breast cancer stage IV breast cancer stage IIIA breast cancer recurrent breast cancer stage IIIB breast cancer stage IIIC breast cancer male breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Vaccines Saponin QA-21V1 Keyhole-limpet hemocyanin Immunologic Factors Physiological Effects of Drugs Adjuvants, Immunologic

2002 Clinical Trials

13909. Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer

: Creatinine no greater than 1.5 times ULN Other: No acute concurrent severe infection No other concurrent significant disease that would preclude study therapy No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: No prior antibody or gene therapy Chemotherapy: No prior cytostatic agents Endocrine therapy: See Disease Characteristics No prior estramustine No prior antiandrogens (e.g., bicalutamide (...) information Responsible Party: Swiss Group for Clinical Cancer Research ClinicalTrials.gov Identifier: Other Study ID Numbers: SAKK 09/01 EU-20139 First Posted: July 1, 2003 Last Update Posted: May 15, 2012 Last Verified: May 2012 Keywords provided by Swiss Group for Clinical Cancer Research: adenocarcinoma of the prostate stage IV prostate cancer recurrent prostate cancer Additional relevant MeSH terms: Layout table for MeSH terms Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms

2002 Clinical Trials

13910. Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer

disorder No greater than grade 2 preexisting peripheral neuropathy No other prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer Able to tolerate steroid premedication PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: More than 6 months since prior adjuvant chemotherapy At least 1 year since prior continuous infusion of fluorouracil or capecitabine At least 1 year since prior taxane administered once (...) by (Responsible Party): Swiss Group for Clinical Cancer Research Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to determine the effectiveness of combining capecitabine and paclitaxel in treating patients who have metastatic breast cancer. Condition or disease Intervention/treatment Phase Breast Cancer

2002 Clinical Trials

13911. Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer

-steroidal anti-inflammatory drugs (NSAIDs) (e.g., asthma, acute rhinitis, nasal polyps, angioneurotic edema, or urticaria) No other malignancy within the past 10 years except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: See Disease Characteristics Other: No concurrent long (...) Campaign Clinical Trials Centre Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Rofecoxib may stop the growth of cancer by stopping blood flow to the tumor and killing tumor cells that remain after surgery. It is not yet known if rofecoxib is effective in treating colorectal cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of giving rofecoxib after surgery in treating patients who have stage II or stage

2002 Clinical Trials

13912. NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer

No other malignancy within the past 2 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No concurrent medical or psychological condition that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics Recovered from prior anticancer chemotherapy No concurrent fluoropyrimidine-based or thymidylate synthase inhibitor agents Endocrine therapy: Not specified Radiotherapy: Recovered from (...) : December 18, 2013 Sponsor: NewBiotics Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of NB1011 in treating patients who have metastatic or recurrent colorectal cancer that has not responded to previous treatment. Condition or disease Intervention/treatment Phase

2002 Clinical Trials

13913. Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

., fluorescein or Bengal-Rose) No abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production test) Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other malignancy within the past 5 years except carcinoma in situ of the cervix, nonmelanoma skin cancer, or second primary squamous cell cancer originating from the head and neck No grade 2 or greater residual ototoxicity or neuropathy from prior platinum-based therapy (...) Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma of the head and neck All primary sites, including oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, and paranasal sinus Recurrent, unresectable, and/or metastatic disease At least 1 measurable lesion At least 20 mm with conventional techniques OR at least 10 mm with spiral CT scan Lesions accessible for biopsy Tumor specimen available for evaluation of epidermal growth factor

2002 Clinical Trials

13914. Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Oncology Group Collaborator: National Cancer Institute (NCI) Information provided by: Gynecologic Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness liposomal doxorubicin in treating patients who have persistent or recurrent cancer of the cervix. Condition or disease Intervention/treatment Phase Cervical Cancer Drug (...) : pegylated liposomal doxorubicin hydrochloride Phase 2 Detailed Description: OBJECTIVES: Determine the antitumor activity of doxorubicin HCl liposome in patients with persistent or recurrent squamous cell carcinoma of the cervix. Determine the toxicity of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive doxorubicin HCl liposome IV over 1 hour on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed

2002 Clinical Trials

13915. Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer

or pelvic CT scan PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-1 OR ECOG 0-1 Life expectancy: At least 5 years Other: No persistent late intestinal or bladder toxicity grade 2 or greater No other major medical or psychiatric illness that would preclude study No metallic hip prosthesis No other malignancy within the past 5 years except localized basal cell or squamous cell skin cancer No other concurrent illness that would limit life expectancy Suitable for spinal or general (...) radioactive material placed directly into or near a tumor to kill tumor cells. Combining hormone therapy with internal radiation may be effective in treating locally recurrent prostate cancer. PURPOSE: Phase II trial to study the effectiveness of hormone therapy followed by internal radiation in treating patients who have locally recurrent prostate cancer following external-beam radiation therapy. Condition or disease Intervention/treatment Phase Prostate Cancer Radiation: brachytherapy Radiation

2002 Clinical Trials

13916. Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

provided by (Responsible Party): National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: This phase II trial is studying erlotinib to see how well it works in treating patients with persistent or recurrent cancer of the cervix. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor Condition or disease Intervention/treatment Phase Cervical Squamous Cell Carcinoma Recurrent Cervical Cancer Drug: erlotinib (...) with squamous cell carcinoma of the cervix receiving OSI-774. II. To determine the duration of progression-free survival and overall survival within this patient population treated with OSI-774. III. Assess the effects of prognostic factors: initial performance status and age. TERTIARY OBJECTIVES: I. To determine epidermal growth factor receptor (EGFR) and p110 truncated EGFR (p110 sEGFR) isoform expression levels in primary tumors, and from tumor samples obtained pretreatment and following four weeks

2002 Clinical Trials

13917. Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

2018 Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Squamous Cell Adenocarcinoma Uterine Cervical Neoplasms Carcinoma, Adenosquamous Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female Neoplasms, Complex and Mixed Paclitaxel Vinorelbine Albumin-Bound Paclitaxel (...) how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix. Drugs used in chemotherapy such as cisplatin, paclitaxel, vinorelbine, gemcitabine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen containing cisplatin is most effective in treating cervical cancer. Condition or disease Intervention/treatment Phase Cervical Adenocarcinoma Cervical

2003 Clinical Trials

13918. 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

No uncontrolled coronary artery disease No uncontrolled arrhythmias Pulmonary No dyspnea at rest No dependence on supplemental oxygen Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study participation No other malignancy except any of the following: Carcinoma in situ of the cervix treated with cone biopsy or resection Nonmetastatic basal cell or squamous cell skin cancer Any stage I malignancy curatively resected more than (...) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving gemcitabine

2003 Clinical Trials

13919. Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer

potentially curative therapy for all prior malignancies No other malignancy within the past 5 years except the following: Effectively treated basal cell or squamous cell skin cancer Carcinoma in situ of the cervix that has been effectively treated by surgery alone Lobular carcinoma in situ of the ipsilateral or contralateral breast treated by surgery alone No evidence of recurrence of any prior malignancy No prior hepatic arterial infusion pump malfunction, malperfusion, or infection PRIOR CONCURRENT (...) Trials in Oncology: stage IV colon cancer adenocarcinoma of the colon adenocarcinoma of the rectum stage IV rectal cancer liver metastases Additional relevant MeSH terms: Layout table for MeSH terms Colorectal Neoplasms Neoplasm Metastasis Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Neoplastic Processes Pathologic Processes Irinotecan

2003 Clinical Trials

13920. Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Hematopoietic Not specified Hepatic Not specified Renal Not specified Other Patients must use effective contraception No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ at any other site No major medical or psychiatric illness that would preclude study therapy No hip prosthesis PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No prior chemotherapy Endocrine therapy Prior neoadjuvant hormonal therapy allowed provided (...) interstitial brachytherapy with external-beam radiation therapy may kill more tumor cells. It is not yet known whether interstitial brachytherapy is more effective with or without external-beam radiation therapy in treating prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of interstitial brachytherapy with or without external-beam radiation therapy in treating patients who have prostate cancer. Condition or disease Intervention/treatment Phase Prostate Cancer Radiation

2003 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>